Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health (NASDAQ:JAGX) has announced new employee inducement grants under Nasdaq Listing Rule 5635(c)(4). Effective October 7, 2024, the company granted restricted stock units (RSUs) to five new employees. New Employee 1 received 80,000 RSUs, which will vest equally over three years, with one-third of the shares vesting each year from the date of hire. New Employees 2-5 each received 15,000 RSUs, which will vest over one year from their respective hire dates.
These RSU grants were approved by Jaguar's Compensation Committee as an inducement for the employees to accept employment with the company. The vesting of the RSUs is contingent on each new employee's continued service with Jaguar through the applicable vesting dates.
Jaguar Health (NASDAQ:JAGX) ha annunciato nuove concessioni di incentivi per i dipendenti ai sensi della Regola di Quotazione del Nasdaq 5635(c)(4). Con effetto dal 7 ottobre 2024, l'azienda ha concesso unità di azioni riservate (RSU) a cinque nuovi dipendenti. Nuovo Dipendente 1 ha ricevuto 80.000 RSU, che matureranno equamente nel corso di tre anni, con un terzo delle azioni che maturerà ogni anno dalla data di assunzione. I nuovi dipendenti 2-5 hanno ricevuto ciascuno 15.000 RSU, che matureranno nel corso di un anno dalla rispettiva data di assunzione.
Queste concessioni di RSU sono state approvate dal Comitato per la Retribuzione di Jaguar come incentivo per i dipendenti ad accettare l'impiego presso l'azienda. Il consolidamento delle RSU è subordinato al continuo servizio di ciascun nuovo dipendente con Jaguar fino alle date di maturazione applicabili.
Jaguar Health (NASDAQ:JAGX) ha anunciado nuevas concesiones de incentivos para empleados bajo la Regla de Cotización 5635(c)(4) de Nasdaq. A partir del 7 de octubre de 2024, la compañía otorgó unidades de acciones restringidas (RSUs) a cinco nuevos empleados. Nuevo Empleado 1 recibió 80,000 RSUs, que se adjudicarán por igual durante tres años, con un tercio de las acciones adjudicándose cada año desde la fecha de contratación. Los Nuevos Empleados 2-5 recibieron cada uno 15,000 RSUs, que se adjudicarán durante un año a partir de sus respectivas fechas de contratación.
Estas concesiones de RSUs fueron aprobadas por el Comité de Compensación de Jaguar como incentivo para que los empleados acepten el empleo en la compañía. La adjudicación de las RSUs está condicionada al servicio continuo de cada nuevo empleado con Jaguar hasta las fechas de adjudicación aplicables.
재규어 헬스(JAGX: NASDAQ)는 나스닥 상장 규정 5635(c)(4) 아래에서 새로운 직원 유인 보조금을 발표했습니다. 2024년 10월 7일부터 회사는 다섯 명의 새로운 직원에게 제한 주식 유닛(RSU)을 부여했습니다. 신규 직원 1은 80,000 RSU를 받았으며, 이는 3년에 걸쳐 동일하게 발생하게 됩니다. 고용일로부터 매년 1/3의 주식이 발생합니다. 신규 직원 2-5는 각각 15,000 RSU를 받았으며, 이는 해당 고용일로부터 1년 동안 발생합니다.
이 RSU 보조금은 직원들이 회사에서의 고용을 수락하도록 유인하기 위해 재규어 보상 위원회에 의해 승인되었습니다. RSU의 발생은 각 신규 직원이 해당 발생 날짜까지 재규어에서 계속 근무하는 것에 달려 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé de nouvelles attributions d'incitations aux employés conformément à la règle de cotation 5635(c)(4) de Nasdaq. À compter du 7 octobre 2024, l'entreprise a accordé des unités d'actions restreintes (RSU) à cinq nouveaux employés. Nouveau Employé 1 a reçu 80 000 RSU, qui vont s'acquérir progressivement sur trois ans, un tiers des actions s'acquérant chaque année à partir de la date d'embauche. Les Nouveaux Employés 2-5 ont chacun reçu 15 000 RSU, qui seront acquises sur une période d'un an à partir de leurs dates d'embauche respectives.
Ces attributions de RSU ont été approuvées par le Comité de Rémunération de Jaguar en tant qu'incitation pour que les employés acceptent un emploi au sein de l'entreprise. L'acquisition des RSU est conditionnée à la continuation du service de chaque nouvel employé avec Jaguar jusqu'aux dates d'acquisition applicables.
Jaguar Health (NASDAQ:JAGX) hat neue Anreizgewährungen für Mitarbeiter gemäß der Nasdaq-Börsenregeln 5635(c)(4) bekannt gegeben. Ab dem 7. Oktober 2024 gewährte das Unternehmen fünf neuen Mitarbeitern eingeschränkte Aktieneinheiten (RSUs). Neuer Mitarbeiter 1 erhielt 80.000 RSUs, die gleichmäßig über drei Jahre ausgegeben werden, wobei ein Drittel der Aktien jedes Jahr ab dem Datum der Einstellung ausgegeben wird. Neue Mitarbeiter 2-5 erhielten jeweils 15.000 RSUs, die über ein Jahr ab dem jeweiligen Einstellungsdatum ausgegeben werden.
Diese RSU-Zuweisungen wurden vom Vergütungsausschuss von Jaguar genehmigt, um die Mitarbeiter zu ermutigen, die Anstellung im Unternehmen anzunehmen. Die Zuteilung der RSUs ist davon abhängig, dass jeder neue Mitarbeiter bis zu den entsprechenden Zuteilungsdaten weiterhin bei Jaguar beschäftigt ist.
- Attraction of new talent through employee inducement grants
- Alignment of employee interests with company performance through RSU grants
- Potential dilution of existing shareholders due to new RSU issuances
SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 RSUs to each of four other new employees ("New Employees 2-5").
The RSUs for New Employee 1 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 1's date of hire. The RSUs for New Employees 2-5 vest over one year starting from each employee's date of hire.
The RSUs for all five new employees were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
How many RSUs did Jaguar Health (JAGX) grant to its new employees on October 7, 2024?
What is the vesting schedule for the RSUs granted by Jaguar Health (JAGX) to its new employees?
Under which Nasdaq rule did Jaguar Health (JAGX) grant these employee inducement RSUs?
Who approved the RSU grants for Jaguar Health's (JAGX) new employees?
